OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunogenic cell death in cancer: concept and therapeutic implications
Lorenzo Galluzzi, Oliver Kepp, Erik C. Hett, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 67

Showing 26-50 of 67 citing articles:

Shifting the paradigm: engaging multicellular networks for cancer therapy
Joyce Hu, Paolo A. Ascierto, Alessandra Cesano, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 3

Chemotherapy drives tertiary lymphoid structures that correlate with ICI-responsive TCF1+CD8+ T cells in metastatic ovarian cancer
Tereza Láníčková, Michal Hensler, Lenka Kašíková, et al.
Clinical Cancer Research (2024), pp. OF1-OF17
Open Access | Times Cited: 3

Intratumoral co‐injection of NK cells and NKG2A‐neutralizing monoclonal antibodies
Ignacio Melero, María C. Ochoa, Carmen Molina, et al.
EMBO Molecular Medicine (2023) Vol. 15, Iss. 11
Open Access | Times Cited: 10

Immunogenic cell stress and death in the treatment of cancer
Hui Pan, Peng Liu, Liwei Zhao, et al.
Seminars in Cell and Developmental Biology (2023) Vol. 156, pp. 11-21
Open Access | Times Cited: 9

Advancing personalized medicine in brain cancer: exploring the role of mRNA vaccines
Feng Lin, Emma Z. Lin, Misa Anekoji, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 8

Immunogenic cell death related mRNAs associated signature to predict immunotherapeutic response in osteosarcoma
Shuai Han, Qinghe Wang, Mingquan Shen, et al.
Heliyon (2024) Vol. 10, Iss. 6, pp. e27630-e27630
Open Access | Times Cited: 2

Nanomaterials: leading immunogenic cell death-based cancer therapies
Changyu Ma, Zhe Cheng, Haotian Tan, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2

Conventional type 1 dendritic cells (cDC1) in cancer immunity
Peng Liu, Liwei Zhao, Guido Kroemer, et al.
Biology Direct (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 7

Withaferin A Increases the Effectiveness of Immune Checkpoint Blocker for the Treatment of Non-Small Cell Lung Cancer
Roukiah Khalil, Ryan J. Green, Kavya Sivakumar, et al.
Cancers (2023) Vol. 15, Iss. 12, pp. 3089-3089
Open Access | Times Cited: 6

Redox Status of Erythrocytes as an Important Factor in Eryptosis and Erythronecroptosis
Anton Tkachenko, Ondřej Havránek
Folia Biologica (2023) Vol. 69, Iss. 4, pp. 116-126
Open Access | Times Cited: 5

Evasion of apoptosis and treatment resistance in squamous cell carcinoma of the head and neck
Ben O’Leary, Heath D. Skinner, Jonathan D. Schoenfeld, et al.
Cancer Treatment Reviews (2024) Vol. 129, pp. 102773-102773
Open Access | Times Cited: 1

Impact of Genomic Mutation on Melanoma Immune Microenvironment and IFN-1 Pathway-Driven Therapeutic Responses
Fátima María Mentucci, Elisa Ayelén Romero Nuñez, Agustina Ercole, et al.
Cancers (2024) Vol. 16, Iss. 14, pp. 2568-2568
Open Access | Times Cited: 1

Synergistic anticancer immunity in metastatic triple-negative breast cancer through an in situ amplifying Peptide-Drug Conjugate
Ha Rin Kim, Seong Jin Park, Young Seok Cho, et al.
Journal of Controlled Release (2024) Vol. 375, pp. 681-697
Closed Access | Times Cited: 1

Regulating tumor cells to awaken T cell antitumor function and enhance melanoma immunotherapy
Weihan Zhang, Shijun Yuan, Zipeng Zhang, et al.
Biomaterials (2024) Vol. 316, pp. 123034-123034
Closed Access | Times Cited: 1

Targeting immunogenic cell death for glioma immunotherapy
Tatiana A. Mishchenko, Victoria D. Turubanova, Ekaterina N. Gorshkova, et al.
Trends in cancer (2023) Vol. 10, Iss. 1, pp. 8-11
Closed Access | Times Cited: 4

Multiple Factors Determine the Oncolytic or Carcinogenic Effects of TLRs Activation in Cancer
Ying-Xiang Yang, C Jin, Anthony E. T. Yeo, et al.
Journal of Immunology Research (2024) Vol. 2024, pp. 1-28
Open Access

Cellular senescence and aging at the crossroad between immunity and cancer
Oliver Kepp, Lorenzo Galluzzi, Giulia Petroni
Methods in cell biology (2024), pp. xvii-xxiv
Closed Access

Combination treatment with PD1/PDL-1 inhibitors for sarcomas: state of the art, next questions
Javier Martín‐Broto, Nadia Hindi, David S. Moura
Current Opinion in Oncology (2024) Vol. 36, Iss. 4, pp. 269-275
Closed Access

Cytofluorometric assessment of calreticulin exposure on CD38+ plasma cells from the human bone marrow
Manuel Beltrán‐Visiedo, Alfonso Serrano del Valle, Nelia Jiménez‐Alduán, et al.
Methods in cell biology (2024), pp. 189-206
Closed Access

Targeted nanoprobe for magnetic resonance imaging-guided enhanced antitumor via synergetic photothermal/immunotherapy
Ruoyu Chen, Xiaowen Lin, Pengyu Tao, et al.
Journal of Colloid and Interface Science (2024) Vol. 678, pp. 937-949
Closed Access

Consequences of the perivascular niche remodeling for tumoricidal T-cell trafficking into metastasis of ovarian cancer
Danuta Kozbor, M. Winkler, N. Malhotra, et al.
Research Square (Research Square) (2024)
Closed Access

Scroll to top